UK: Predictions Of A No-Deal Brexit Are Rising…But For The Life Sciences Sector, Will "Science Prevail" Over The Brexit "Doom And Gloom"?

Last Updated: 12 July 2019
Article by Caroline Scott, Paul Hardy and Sam Mitchell

Brexit is highly fluid; accordingly the legal situation and advice within this article is subject to change. This article assumes a no-deal Brexit (Hard Brexit) and highlights the key UK Government, MHRA and EMA guidance, proposed legal changes and practical consequences of a Hard Brexit on medicines, medical devices, clinical trials, manufacturing and supply. For a more in depth analysis, download DLA Piper's free interactive Brexit guide for companies in the life sciences sector - available here.

The current political back-drop

Following Prime Minister Theresa May's resignation announcement and the overwhelming support for the new Brexit Party in the European Parliamentary Elections, the likelihood of a Hard Brexit continues to increase. The House of Commons remains deadlocked and, at the time of writing, there is still no prospect of the Withdrawal Agreement being agreed when it comes before the House at the beginning of June, for the following reasons:

  • the break down in cross-party Brexit talks earlier in May;
  • the number of Brexiteers in the Conservative Party leadership race who support a Hard Brexit; and
  • the significant wins of the Brexit Party, and conversely the losses suffered by both the Conservatives and Labour during the European Parliamentary elections.

On 10 April 2019, the EU agreed to delay Brexit to 31 October 2019 provided the UK ratifies the Withdrawal Agreement and, if not ratified by 22 May 2019, the UK holds European Parliament elections. These have now been held.

However, a Hard Brexit is still possible if the Withdrawal Agreement is not ratified between now and, at the latest, 31 October 2019 (Exit Date), although a further extension has not been ruled out. If the Withdrawal Agreement is ratified before Exit Date the UK will leave the EU on the first day of the following month. If the UK fails to ratify the Withdrawal Agreement by Exit Date, the fate of Brexit is in the hands of the EU: by law, one Member State can veto a further extension, although in practice, a number of Member States will have to oppose an extension.

Set against a backdrop of both the UK and EU's patience wearing thin over the inability of the Government and Parliament to reach agreement on any way forward, continued uncertainty and stockpiles of medicines sitting unused to date interfering with cash flow and profits, it would not be surprising if the life sciences sector felt disheartened or cautious about investment in the UK.

Is it all doom and gloom?

The prevailing message from recent conferences is that any challenges for the sector, from Brexit or otherwise, is: "science prevails". Companies are still highly committed to collaborations across borders and investment in the UK's flagship life sciences sector to advance science and improve healthcare. For example, Astrazeneca and GSK are still committing to the UK, with the former in the midst of developing its GBP500+ million global headquarters and R&D hub in Cambridge. Other UK Government industry partners such as GW Pharmaceuticals, Roche, Celgen, IQVIA Ltd and Oxford Biomedica have committed over GBP200 million of new investment.

Businesses should also be encouraged by:

  • the Life Sciences Sector Deals;
  • the UK government's pledge to increase public investment to GBP12.5 billion for 2012/22 and increase investment in R&D to 2.4% of GDP by 2027;
  • GBP79 million commitment by the UK Government to the new "Accelerating detection of disease" challenge;
  • The Wellcome Trust commitment of GBP250 million to their Leap Fund for high risk, high reward pioneering sciences; and
  • the detailed Brexit guidance issued by the UK Government, MHRA and EMA, and the steps the UK Government has progressively taken to prepare for Brexit, including the Contingency Legislation.

British Patent Attorneys contribute over GBP1 billion to the UK economy so it is good news that Brexit does not appear to be having an impact so far on the number of European patent applications filed by British patent attorneys. This will be largely down to:

  • neither the UK Intellectual Property Office nor the European Patent Office are EU institutions and will therefore continue to assess patent applications in the same way as before Brexit;
  • granted EU patents will remain effective in the UK post-Brexit; and
  • the UK will continue to be a contracting state to the European Patent Convention and remain a member of the Paris Convention, both of which are critical for the protection of patents in Europe and beyond.

Key themes and changes

Below we have highlighted some key themes and changes arising particularly from a Hard Brexit:

  • Loss of "one-stop" shop regime and cessation of participation in the EU regulatory network: e.g. for cross-border data processing and dual UK/EU oversight on data protection; separate market authorisations ("MA") will be required for the UK and EU; loss of coordination of clinical trials across the European medicines regulatory network;
  • New requirement for presence of regulated individuals within organisations in the UK to market in the UK: e.g. the new role of the UK Responsible Person for the placing of devices on the UK market, and for medicines the requirement for the MA holder to be established in the UK (or have a UK contact person in the UK within 4 weeks of Exit Date until this is possible);
  • To continue to market in the EU/EEA, the requirement to move marketing operations based in the UK to a country in the EEA:

    • the MA, Qualified Person for Pharmacovigilance (QPPV) (and Pharmacovigilance System Master File), Reference Member State (in respect of the Mutual Recognition Procedure or Decentralised Procedure: after Brexit the UK cannot act as such) need to be in the EEA, and conversely the foregoing must be based in the UK by 31 December 2020 to continue to market in the UK;
    • each batch of finished product must be certified by a Qualified Person of the manufacturer and/or importer within the EEA (and noted in the MA) and the batch release site must be established in the EEA or a country which has a Mutual Recognition Agreement (MRA) with the UK;
  • Extra administrative burden to comply with UK & EU/EEA regulatory changes:
    For the EU market, e.g.:

    • introducing an EEA importation site for finished medicinal products manufactured in the UK to market in the EU/EEA;
    • re-authorisation of UK approved CE marks by an EU notified body to place devices on EU/EEA market;
    • changing UK-based applicants to non-UK based applicants for on-going MA applications;
    • ensuring clinical trial sponsors are based in the EEA for pan-European trials;

    For the UK market, e.g.:

    • filing of a complete set of regulatory data in the UK to obtain UK market authorisations to market generics or biosimilars;
    • ensuring clinical trial sponsors are either based: (i) in the UK; or (ii) in a country on an approved list, which will include EU/EEA countries;
    • Parallel Import Licence holders will need to be located in the UK within 21 months of Exit Date, and in any event should appoint a contact person in the UK within 4 weeks of Exit Date;
    • registration with the MHRA of medical devices, active implantable medical devices, IVDs and custom medical devices and their manufacturers (who must have a UK-registered place of business (or a UK Responsible Person registering on its behalf));
    For both markets, e.g.:

    • for new devices, requirement for authorisation by an EU notified body;
    • requirement to amend packaging and leaflets for medicinal products already on the UK market by the end of 2021 (e.g. to update the local representative mentioned in the product information);
    • Recognition of EU rights in the UK but not fully reciprocated by the EU: e.g.
    • automatic "grandfathering" of MAs for existing Centrally Authorised Products (CAPs) to UK MAs;
    • for a limited unspecified period post-Brexit, continued recognition in the UK of CE marks approved by EU notified bodies for medical devices and parallel imports from EU to UK. However, batch testing for compliance may still be needed in the EU in respect of imports from the UK into the EU.
    • immediate restrictions on the transfer of personal data from the EU to the UK (but not vice versa);
    • continued acceptance in the UK of human medicines and Investigational Medicinal Products in the EEA or a country which has a MRA with the UK;
  • New equivalent UK rights: creation of a UK SPC system under the UK Contingency Legislation akin to the current EU system, and equivalent provisions for Paediatric Extensions, and simplification of the process for Paediatric Investigation Plans; potential new UK falsified medicines regulatory framework;
  • Potential medicine shortages and dangerously high increases in stockpiling: since January 2019 new statutory reporting requirements relating to medicines shortages and discontinuations have been in place and the Department of Health and Social Care requires MA holders to ensure resilience of supplies and strategies to address impending shortages;
  • Access to European initiatives and collaborative projects, funding and workforce is in jeopardy: current benefits include European funding (such as Horizon 2020), European collaboration (such as the Innovative Medicines Initiative), access to skilled EU workers and mutual cooperation between EU institutions (e.g. in respect of conducting clinical trials and automatic sharing of pharmacovigilance and post-market safety data); and
  • The MHRA, the UK's stand-alone medicines and medical devices regulator, subsuming specific EMA functions.

Brexit planning: Better late than never

As the likelihood of a Hard Brexit increases, companies should urgently commence (or continue) Brexit planning and use the extension wisely, for example taking the following steps:

  • Understand the differing approaches of the UK and the EU to Brexit: the UK is being pragmatic and aiming to mitigate the impact of Brexit by continuing to recognise the validity of many goods and services imported from the EU. Conversely, the EU will treat the UK as a "third country" (i.e. outside the Single Market and the Customs Union), for the purposes of importing goods and services into the EU. Therefore, there will be no preferential treatment for UK goods and services.
  • Grasp an understanding of the mitigating measures put in place by the UK Government and the relevant third country rules which will apply to your business: e.g. as detailed in this article, but more detailed guidance relating to medicinal products for human and veterinary use within the framework of the centralised procedure is available here, more general guidance can be found here, guidance on trading goods with the EU can be found here, services here, and placing manufactured goods on the UK market (excepting medical devices) if there is a Hard Brexit can be found here);
  • Analyse your business to understand the EU rights which the business relies upon and implement a mitigation strategy: e.g. consider re-structuring the business' supply chain to: (i) address the reversion to WTO terms which impose tariffs, clearance procedures and increase the risk of delays for products imported into the UK; and (ii) mitigate the consequential risk of degradation and loss of drugs with particular storage conditions and shelf lives;
  • "Re-paper" existing contractual arrangements to incorporate the standard contractual clauses: in the event of a Hard Brexit immediate restrictions will be placed on EU-UK personal data transfers (but not vice versa);
  • Establish regulatory persons in the UK: a MA holder and QPPV in the UK and transfer MAs to holders in the UK or EEA to continue to market in the UK or EEA respectively; and
  • For EU/EEA markets: use EU-based notified bodies and establish trial sponsors in the EU/EEA.

Like many things in life, preparation is the key to success.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions